Login to Your Account



Acquisition Option Plus Potential $1.1B in Milestones

Celgene Pays Acetylon $100M for HDACs, Full Buyout Option

By Randy Osborne
Staff Writer

Monday, July 29, 2013
Acetylon Pharmaceuticals Inc.'s $100 million up-front deal with Celgene Corp. for selective histone deacetylase (HDAC) inhibitors includes an option to take over the company for at least $500 million more, in an agreement that includes milestone payments of as much as $1.1 billion: $250 million for regulatory goals, and $850 million for hitting sales targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription